title: Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.
abstract: OBJECTIVE
  It was the aim of this study to test the hypothesis that the voltage-gated sodium channel gene SCN2A R19K polymorphism confers liability to oxaliplatin-induced peripheral neuropathy (OXLIPN).
  
  
  METHODS
  Sixty-two patients with advanced colorectal cancer were genotyped, using allele-specific primers and SYBR green in real-time polymerase chain reaction. All patients had received adjuvant oxalipla-tin-based chemotherapy. The severity of OXLIPN was defined by means of the clinical total neuropathy score. Following the discontinuation of treatment, 36/62 patients (58.1%) developed OXLIPN. Grade I neurotoxicity was revealed in 14 (38.9%) patients and grade II neurotoxicity in 22 (61.1%) patients.
  
  
  RESULTS
  From patients without OXLIPN (n = 26), 80.8% (n = 21) were homozygous for G, 19.2% (n = 5) were heterozygous (AG) and none was homozygous for A. The corresponding percentages for patients developing any grade of OXLIPN (n = 36) were similar. Likewise, among patients experiencing OXLIPN, insignificant differences in R19K genotypes were revealed between those with grade I versus grade II neurotoxicity.
  
  
  CONCLUSIONS
  Our study failed to provide evidence to support a causal relationship between the SCN2A R19K polymorphism and OXLIPN.
authors.affiliation: Division of Clinical Oncology, Department of Medicine, University Hospital of Patras, Rion-Patras, Greece.
authors.forename: Andreas A
authors.initials: AA
authors.lastname: Argyriou
authors.forename: Anna G
authors.initials: AG
authors.lastname: Antonacopoulou
authors.forename: Chrisoula D
authors.initials: CD
authors.lastname: Scopa
authors.forename: Anastasia
authors.initials: A
authors.lastname: Kottorou
authors.forename: Athina
authors.initials: A
authors.lastname: Kominea
authors.forename: Stavros
authors.initials: S
authors.lastname: Peroukides
authors.forename: Haralabos P
authors.initials: HP
authors.lastname: Kalofonos
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062551:NAV1.2 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins / Q000235:genetics*; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011110:Polymorphism, Genetic; D015222:Sodium Channels / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D062551:NAV1.2 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins; D009944:Organoplatinum Compounds; C568251:SCN2A protein, human; D015222:Sodium Channels; D000077150:Oxaliplatin